The Landscape is a database that compiles and summarizes publicly available information on the global R&D pipeline of universal, broadly protective, and next-generation influenza vaccine candidates, as defined in the Influenza Vaccines R&D Roadmap (IVR). Vaccine candidates profiled in the Landscape are designed to provide broader and more durable protection against seasonal and pandemic influenza, compared with current strain-specific influenza vaccines.
CIDRAP initiated development of the Landscape with support from the Global Funders Consortium for Universal Influenza Vaccine Development (2019-2024) and currently receives support from the Collaborative Influenza Vaccine Innovation Centers (CIVICs), US National Institute of Allergy and Infectious Diseases (NIAID).
Database last updated on Jun 30, 2025
Recent Updates
Reactogenicity, safety, and immunogenicity of Osivax’s NP-based OVX836 vaccine candidate co-administered with a licensed seasonal influenza vaccine in a Phase 2a trial NCT05284799, published in Groth 2025
Preclinical evaluation of intranasal delivery of a multi-subtype consensus NA-M2e VLP vaccine candidate, reported in Raha 2025
Development of recombinant H3 COBRA HA antigens using A(H3N2) HA sequences circulating from 2018-2022 to elicit broadly protective antibodies against A(H3N2) strains in animal models, reported in Allen 2025
Results of a Phase 3 trial NCT06097273 of Moderna’s mRNA-1083 combination COVID+influenza vaccine candidate, published in Rudman Spergel 2025
Preclinical evaluation of a centralized consensus NA immunogen delivered via an adenovirus vector, reported in Pekarek 2025
Results of a Phase 1/2 trial NCT05052697 of Pfizer’s next-generation quadrivalent mRNA vaccine candidate, qIRV, reported in Branche 2025
Database
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|
Approved
|
|---|---|---|---|---|
|
Platform
Influenza virus-based |
||||
|
17
Vaccines in
Preclinical
|
2
Vaccines in
Phase 1
|
5
Vaccines in
Phase 2
|
0
Vaccines in
Phase 3
|
0
Vaccines in
Approved
|
|
|
|
|
|
|
|
Platform
Nucleic acid-based |
||||
|
30
Vaccines in
Preclinical
|
6
Vaccines in
Phase 1
|
6
Vaccines in
Phase 2
|
4
Vaccines in
Phase 3
|
0
Vaccines in
Approved
|
|
|
|
|
|
|
|
Platform
Non-VLP nanoparticles |
||||
|
52
Vaccines in
Preclinical
|
4
Vaccines in
Phase 1
|
1
Vaccines in
Phase 2
|
2
Vaccines in
Phase 3
|
0
Vaccines in
Approved
|
|
|
|
|
|
|
|
Platform
Recombinant proteins |
||||
|
32
Vaccines in
Preclinical
|
1
Vaccines in
Phase 1
|
3
Vaccines in
Phase 2
|
1
Vaccines in
Phase 3
|
0
Vaccines in
Approved
|
|
|
|
|
|
|
|
Platform
Virus-like particles (VLP) |
||||
|
20
Vaccines in
Preclinical
|
1
Vaccines in
Phase 1
|
0
Vaccines in
Phase 2
|
1
Vaccines in
Phase 3
|
0
Vaccines in
Approved
|
|
|
|
|
|
|
|
Platform
Virus-vectored |
||||
|
23
Vaccines in
Preclinical
|
2
Vaccines in
Phase 1
|
3
Vaccines in
Phase 2
|
0
Vaccines in
Phase 3
|
0
Vaccines in
Approved
|
|
|
|
|
|
|
| Vaccine Name | Developer / Location | Platform | Phase Sort ascending | Approach & Sources |
|---|---|---|---|---|
Multivalent DNA nanovaccine |
Taizhou University (China) | Non-VLP nanoparticles | Preclinical | pβH7N2SH9/DGL NPs developed by encapsulating the pβH7N2SH9 within the dendrigraft poly-l-lysines nanoparticles |
HA2-16 ferritin nanoparticles |
Jilin University (China) | Non-VLP nanoparticles | Preclinical | A recombinant ferritin that incorporates a linear conserved stem epitope (HA2-16) derived from the HA2 region |
Ad vector-based vaccine with autophagy-inducing peptide |
Purdue University (US) | Virus-vectored | Preclinical | Adenovirus vector-based vaccine expressing a combination of antigens including HA signal peptide (SP), HA stem and the autophagy-inducing peptide C5 (AIP-C5); aimed at enhancing immune responses and cross-protection. Wang 2025 (PMID: 39852874), Sayedahmed 2024 (PMID: 38400140), Sayedahmed 2020 (PMID: 33019589), Hassan 2017 (PMID: 29023601), Patent: Methods and Compositions for Vaccination Against Heterosubtypic Influenza Viruses Using an Adenoviral Vector Leading to Enhanced T Cell Response Through Autophagy (US20250152696)
|
mRNA/LNP vaccine |
Merck & Co. (US) | Nucleic acid-based | Preclinical | LNP-encapsulated chemically modified mRNA vaccines encoding various forms of influenza antigens |
rAd-NP-M2e-GFP |
Jilin University (China) | Virus-vectored | Preclinical | Packaged recombinant adenovirus rAd-NP-M2e-GFP expressing multiple copies of influenza virus conserved antigens NP and M2e and packaged empty vector adenovirus rAd-GFP |
Mini-HA-LS Nano-vaccine |
Huazhong Agricultural University (China) | Non-VLP nanoparticles | Preclinical | Mini-HA proteins expressed on lumazine synthase (LS) nanoparticles by SpyTag/SpyCatcher aimed at eliciting potent immune responses |
N2-VLPs |
University of Natural Resources and Life Sciences Vienna (BOKU) (Austria) | Virus-like particles (VLP) | Preclinical | VLPs generated in insect cells, that are based on self-assembly and budding of the human immunodeficiency virus 1 (HIV-1) gag protein, and display N2 NA on their surface |
20 mRNA-LNP |
CIVICs, NIAID (US), University of Pennsylvania (US) | Nucleic acid-based | Preclinical | Nucleoside modified mRNA vaccine constructs encoding either conserved antigens, or hemagglutinin antigens from all 20 known influenza A and B virus subtypes aimed at inducing antigen-specific cellular and humoral immune responses to protect against diverse influenza virus strains. Kirby 2023 (PMID: 36708722), Villanueva 2023 (PMID: 36631700), Gouma 2022 (PMID: 36533954), Pecetta 2022, O'Leary 2022 (PMID: 36450841), Kelvin 2022 (PMID: 36423290), Arevalo 2022 (PMID: 36423275), McMahon 2022 (PMID: 36322769), Pardi 2022 (PMID: 35945226), Muramatsu 2022 (PMID: 35131437), Alameh 2021, Freyn 2021 (PMID: 34485597), Willis 2020 (PMID: 31915303), Freyn 2020 (PMID: 32359470), Pardi 2018 (PMID: 30135514), Limberis 2013 (PMID: 23720583), News Story 2023, Press Release 12-6-2022, Press Release 12-6-2022, Press Release 11-25-2022, Patent: Universal influenza vaccine and methods and use (US20240374708A1), Patent: Universal influenza vaccine using nucleoside-modified mRNA, NIH Funding, NIH Funding
|
Hybrid fusion protein combination vaccine |
Emory University (US), Georgia State University (US) | Virus-like particles (VLP) | Preclinical | Combination influenza and SARS-CoV-2 (COVID-19) VLP vaccine that uses influenza virus-like particles (VLP) incorporated by protein transfer with glycosylphosphatidylinositol (GPI)-anchored SARS-CoV-2 RBD fused to GM-CSF as an adjuvant |
TX98-129 |
University of South Dakota (US), University of Illinois Urbana-Champaign (US) | Influenza virus-based | Preclinical | Recombinant influenza virus based vaccine that expresses a chimeric HA (HA-129) derived from HAs of four genetically distinct swine influenza A viruses (H1N1) that had a history of zoonotic transmission. The chimeric HA was obtained through molecular breeding (gene shuffling) technology from the four original parental HAs. Designed to induce broadly protective immunity against genetically divergent HAs. |
HAsd protein |
Southwest Jiaotong University College of Medicine (China) | Recombinant proteins | Preclinical | Recombinant protein based construct targeting the HA stalk domain (HAsd) displayed on the surface of L. lactis; aimed at providing cross-immunity against divergent influenza A viruses. |
H1-based cHAs |
University of Ghana (Ghana) | Recombinant proteins | Preclinical | Chimeric HAs (cHAs) generated with consensus sequence building aimed at inducing cross-reactive antibodies. |
PLGA nanoparticles |
Sunway University (Malaysia) | Non-VLP nanoparticles | Preclinical | Self-adjuvanting PLGA nanoparticles encapsulating six conserved peptides |
AdC-Flu-Tet |
Fudan University (China) | Virus-vectored | Preclinical | The HA genes of influenza B Yamagata (BY) and Victoria (BV) strains, and the NP gene of H1N1 cloned into the E1 region of the chimpanzee adenoviral vector, AdC68, and M2e epitopes of H1N1 and H3N2 were fused to the loop region of the AdC68 fiber, resulting in the recombinant adenoviral vector vaccine, AdC-Flu-Tet |
Wyeth/IL-15/5flu |
University of Hong Kong (Hong Kong SAR, China) | Virus-vectored | Preclinical |
Live, replication competent vaccinia Wyeth Backbone carrying 5 full-length influenza proteins derived from H5N1 viruses (NP, HA NA, M1, and M2) and IL-15 as a molecular adjuvant; aimed at eliciting robust CD4+ and CD8+ T cell responses. |
HA-encoding mRNA |
University of Georgia (US) | Nucleic acid-based | Preclinical | Novel quadrivalent mRNA influenza vaccine encoding hemagglutinin (HA) proteins. |
H3N8 live attenuated virus vaccine |
Iowa State University (US) | Influenza virus-based | Preclinical | Live attenuated equine influenza virus (LAIV) equine H3N8 vaccine to induce broad protection without the need for non-influenza viral vectors, multiple HAs, or foreign protein scaffolds common to other universal influenza vaccine candidates. |
H1c-mRNA-LNP |
National Engineering Technology Research Center for Combined Vaccines (China) | Nucleic acid-based | Preclinical | A lipid nanoparticle (LNP)-encapsulated nucleoside-modified mRNA vaccine (mRNA-LNPs) that encodes a consensus full-length HA sequence (H1c) |
HA-clamp proteins |
University of Queensland (Australia) | Recombinant proteins | Preclinical | Molecular clamp which utilizes the highly stable trimerization domain to allow for efficient production and purification of conformationally stabilized perfusion hemagglutinin HA |
Helix-A stem nanoparticle |
NIAID (US) | Non-VLP nanoparticles | Preclinical | Nanoparticle-based vaccine that displays multiple copies of the conserved influenza helix-A region per nanoparticle subunit |
rMVA-PE |
University of Veterinary Medicine (Germany) | Virus-vectored | Preclinical | An artificial immunogen that comprises of twenty highly conserved influenza virus CD8 +T cell epitopes delivered using the highly attenuated viral vector Modified Vaccinia virus Ankara (MVA) |
NA-VLPs |
King Mongkut's University of Technology Thonburi (Thailand) | Virus-like particles (VLP) | Preclinical | Recombinant NA protein synthesized and assembled into VLPs, aimed at inducing anti-NA antibodies |
dbDNA-encoded NA |
Imperial College London (UK) | Nucleic acid-based | Preclinical | Influenza virus vaccines made using a closed linear DNA platform, Doggybone™ DNA (dbDNA), produced by a rapid and scalable cell-free method and encoding NA |
pABOL-formulated saRNA vaccine |
Imperial College London (UK) | Nucleic acid-based | Preclinical | Bioreducible cationic polymer, pABOL used for the delivery of a self-amplifying RNA (saRNA) vaccine expressing either haemagglutinin (HA) from H1N1 or H3N2 influenza virus in a prime boost regime |
NA-targeting circRNA vaccine |
Sun Yat-sen University (China) | Nucleic acid-based | Preclinical | Circular RNA (circRNA) vaccines containing N1, N2, and influenza B virus NA antigens to elicit broad-spectrum NA immunity against heterologous influenza |
rNP plus BPPcysMPEG |
Helmholtz Centre for Infection Research (Germany), Instituto de Medicina y Biología Experimental de Cuyo (IMBECU) (Argentina) | Recombinant proteins | Preclinical | Recombinant protein based vaccine containing the NP antigen adjuvanted with a TLR2/6 agonist, the BPPcysMPEG adjuvant |
NMHC |
Chinese Academy of Sciences (China) | Recombinant proteins | Preclinical | Recombinant protein, NMHC, consisting of viral conserved epitopes and a superantigen fragment |
MLN-mRNA |
Shanghai Institute of Biological Products (China) | Nucleic acid-based | Preclinical | A novel mRNA-based multiantigen influenza vaccine based on a single mRNA molecule with a tandem of three conserved antigens of influenza A virus, including the ectodomain of the M2 ion channel (M2e), the long alpha helix of haemagglutinin stalk region (LAH), and nucleoprotein (NP) |
Adjuvanted PNP-hydrogel system |
Stanford University (US) | Non-VLP nanoparticles | Preclinical | Sustained delivery of multivalent influenza vaccines from a next-gen injectable polymer-nanoparticle (PNP) hydrogel technology |
Adjuvanted nanoparticle fusion constructs |
Indian Institute of Science (India) | Non-VLP nanoparticles | Preclinical | Trimeric influenza stem domain immunogen, pH1HA10, displayed on the ferritin like protein MsDps2, Ferritin, and Encapsulin |
Sbmut HA |
Duke University (US) | Recombinant proteins | Preclinical | An HA antigenic mixture–based vaccine with four positions of the Sb antigenic site randomized within the back-bone of an H1 HA |
PROTAR |
Chinese Academy of Sciences (China) | Influenza virus-based | Preclinical | A library of live attenuated influenza vaccines created by using diverse cellular E3 ubiquitin ligases to generate proteolysis-targeting (PROTAR) influenza A viruses. The PROTAR viruses were engineered to be attenuated by the ubiquitin–proteasome system, which mediates viral protein degradation in conventional host cells, but allows efficient replication in engineered cell lines for large-scale manufacturing. (Formerly: PROTAC) Zhang 2025 (PMID: 39814992), Shen 2025 (PMID: 39815008), Si 2022 (PMID: 35788567), Gilbertson 2022 (PMID: 35869290), Li 2022 (PMID: 36281705), Patent: Proteolysis-Targeting Virus, Live Vaccine Thereof, Preparation Method and Use Thereof, Patent: Recombinant Virus Containing Degron, Preparation Method Therefor, and Application Thereof
|
Mosaic NA1 (mNA1) |
Sun Yat-sen University (China) | Nucleic acid-based | Preclinical | A series of genetic algorithm-based mosaic NA1 (mNA1) designed, then cloned into recombinant DNA and replication-defective Vesicular Stomatitis Virus (VSV) vector |
Combinatorial polymeric nanoshell |
National Taiwan University (Taiwan) | Non-VLP nanoparticles | Preclinical | Nanoshell vaccine with co-encapsulation of peptides aimed at inducing a T cell response. |
AH3–GFP |
Vaxsia Biomedical (Taiwan), University of Maryland Baltimore County (US) | Non-VLP nanoparticles | Preclinical | Self-assembled protein nanoparticle composed of a gain-of-function mutant of the AH3 peptide that enables temperature- and salt-dependent protein nanoparticle thermostability, intended to to stimulate a long-lasting humoral immune response, mediated by the presence of thermal stable protein nanoparticle that remains intact in the injection site |
Inverted HA-extracellular vesicles (EVs) |
Georgia State University (US) | Non-VLP nanoparticles | Preclinical | Upside-down (inverted) influenza HA configuration that exposes the conserved HA stalk region while partially hiding the globular head domain created by conjugating influenza hemagglutinin (HA) onto EV (cell-derived extracellular vesicles) surfaces through HA-receptor interaction; administered intranasally |
GammaFlu |
Gamma Vaccines (Australia) | Influenza virus-based | Preclinical | Whole influenza virus inactivated with gamma irradiation to prevent viral replication, leaving the external and internal protein antigens intact; aimed at stimulating antibodies and cytotoxic T-cells to provide cross-protective immunity; intranasal administration. |
M2e VLP MP |
Mercer University (US) | Virus-like particles (VLP) | Preclinical | Adjuvanted M2e based VLP encapsulated into a micro particulate matrix |
Mosaic VLPs |
Sun Yat-sen University (China) | Virus-like particles (VLP) | Preclinical | An HA and NA mosaic immunogen cocktail containing a broad range of epitopes targeting both IAV and IBV expressed as virus-like particles (VLPs) |
HAdV5-HNH |
China CDC (China) | Virus-vectored | Preclinical | Adenovirus type 5 based vector vaccine (HAdV5-HNH) carrying the conserved influenza antigens HA stem and NA |
HBc VLPs |
Chinese Academy of Sciences (China) | Virus-like particles (VLP) | Preclinical | Biomimetic dual-antigen hybrid nanovaccine VLP construct with interior NP and exterior M2e antigens, using a hepatitis B virus core (HBc) VLP; aimed at inducing a cross-protective immune response. |
Epigraph HA |
University of Nebraska−Lincoln (US) | Virus-vectored | Preclinical | Vaccine designed using the Epigraph vaccine antigen designer, which uses a graph-based algorithm to create vaccine antigens with maximized potential epitope coverage of a highly diverse sequence population. For example, a universal swH3 vaccine by computationally designing a cocktail of three swH3 hemagglutinins (HA), or immunogens designed against the HA protein of IBV (IBV-Epi), or multivalent viral-vectored vaccine (rAd-Tri-Vic) targeting IBV. |
M2e Nanoclusters |
Texas Tech University (US), Georgia State University (US) | Non-VLP nanoparticles | Preclinical | Unadjuvanted cross linked M2e nanoclusters (NCs) Status: Active |
Chimeric cytokine HA-VLP vaccine |
Nerome Institute of Biological Resources (Japan) | Virus-like particles (VLP) | Preclinical | VLPs containing a chimeric cytokine (CC) comprising the M2 protein, influenza A neuraminidase stalk |
hlHA IIV |
CIVICs, NIAID (US), Duke University (US) | Influenza virus-based | Preclinical | Authentic influenza A virus (IAV) particles that harbor “headless” HA (hlHA) along with the normal complement of other viral proteins to serve as an inactivated influenza vaccine (IIV) |
HA/GP nanoparticles |
Georgia State University (US) | Non-VLP nanoparticles | Preclinical | Polyethyleneimine-functionalized graphene oxide nanoparticles (GP nanoparticles); administered intranasally; aimed at enhancing HA immunogenicity |
HA-T-AGM Protein |
Translational Health Science & Technology Institute (India) | Recombinant proteins | Preclinical | A recombinant full-length soluble trimeric HA protein expressed in mammalian Expi293F expression system administered intradermally and with Addavax adjuvant |
P125-H |
China CDC (China) | Recombinant proteins | Preclinical | Multiple polypeptides derived from highly conserved regions of influenza virus proteins hemagglutinin (HA), neuraminidase (NA), and matrix protein 2 (M2) linked using Ii-Key technology; administered via intraperitoneal injection with MF59 adjuvant |
NAe-HA and M2e-HA |
Georgia State University (US) | Influenza virus-based | Preclinical | Inactivated, replication-competent recombinant influenza virus expressing chimeric HA molecules with a conserved NA epitope (NAe) or conserved matrix protein (M2e) or chimeric 4xM2e-HA fusion proteins with 4M2e epitopes inserted into the H3 HA N-terminus; aimed at inducing antibody responses to conserved epitopes for heterosubtypic immunity. |
Liposomal peptide vaccine |
Griffith University (Australia) | Non-VLP nanoparticles | Preclinical | Liposomal vaccine adjuvanted with the TLR4 agonist, 3D-PHAD, and express the conserved influenza A M2e epitope |
DVX-pan-H5Nx |
University of Cambridge (UK), DIOSynVax (UK) | Nucleic acid-based | Preclinical | Digitally Immune Optimised Synthetic Vaccine (DIOSynVax) technology used to select cross-reactive antigens and combine different classes of the best antigen combinations into mRNA vaccine antigen payloads (VAP) to create a broadly protective, thermostable mRNA vaccine candidate, DVX-pan-H5Nx |
Cap-Cat VLPs |
Henan Academy of Agricultural Sciences (China), Zhengzhou University (China) | Virus-like particles (VLP) | Preclinical | A generalized nanoantigen display platform, Cap-Cat virus-like particles (VLPs) displaying antigens such as M2e; aimed at providing cross-protection against diverse subtypes of influenza A virus strains. Formerly: Cap-M2e VLP |
H2-CON |
University of Nebraska−Lincoln (US) | Virus-vectored | Preclinical | Adenoviral-vectored centralized consensus HA construct against H2 influenza A virus, designed to induce broadly protective antibody titers when delivered in a prime-boost strategy first by Ad6 and followed with Ad5. |
HA, NP, and 3M2e mRNA |
Chinese PLA General Hospital (China) | Nucleic acid-based | Preclinical | mRNA vaccine encoding influenza hemagglutinin (HA), nucleoprotein (NP), and three tandem repeats of matrix protein 2 (3M2e). |
Conjugate vaccine and P8 carrier peptide |
TRIA Bioscience (US) | Non-VLP nanoparticles | Preclinical | Nanoparticle-based peptide containing the highly conserved alpha-helical domain within the influenza HA stem (peptides modified with the Helix A epitope); GLA-SE adjuvanted and aimed at inducing functional antibodies to small molecules and protein-based epitopes. |
cGAMP-adjuvanted multivalent mRNA vaccines |
Georgia State University (US) | Nucleic acid-based | Preclinical | A multivalent influenza mRNA lipid nanoparticle (LNP) vaccine with mRNAs of hemagglutinins from influenza H1N1 and H3N2 viruses, matrix protein 1, and nucleoprotein, adjuvanted with cGAMP |
HAm |
Sun Yat-sen University (China) | Recombinant proteins | Preclinical | Stabilized trimeric recombinant mosaic HA proteins named HAm, expressed using a protein-based vaccine platform |
T4-M2e VLP |
Huazhong Agricultural University (China) | Virus-like particles (VLP) | Preclinical | T4 VLP construct displaying three tandem copies of M2e from human, swine and avian influenza; aimed at inducing both humoral and cellular immune responses. |
ISCOMs/MPLA-adjuvanted SDAD protein nanoparticles |
Georgia State University (US) | Non-VLP nanoparticles | Preclinical | A core/shell protein nanoparticle consisting of influenza nucleoprotein (NP) as the core and NA1-M2e or NA2-M2e fusion proteins as the coating antigens by SDAD hetero-bifunctional crosslinking boosted by immune-stimulating complexes (ISCOMs)/monophosphoryl lipid A (MPLA) adjuvants |
NS1-truncated influenza viruses |
Russian Ministry of Health (Russia) | Influenza virus-based | Preclinical | Influenza viruses with truncated NS1 proteins, which lack the N-terminal half of the NS1 protein, that are unable to antagonise the innate immune response; administered intranasally |
Quadrivalent HA mRNA |
Greenlight Biosciences (US) | Nucleic acid-based | Preclinical | Quadrivalent mRNA vaccine encoding HA from four seasonal influenza viruses |
M2e/NP Dual Epitope-Displaying Nanoparticles |
Guangzhou Medical University (China) | Non-VLP nanoparticles | Preclinical | A modular vaccine strategy pairing a clinical-stage adjuvanted recombinant hemagglutinin (HA) vaccine (SCVC101) with OMN, a heptameric nanoparticle displaying conserved influenza A virus T-cell epitopes from nucleoprotein (NP) and matrix 2 ectodomain (M2e) |
M2e-H3 stalk |
Georgia State University (US) | Recombinant proteins | Preclinical | Chimeric M2e and H3 hemagglutinin (HA) stalk protein vaccine engineered by genetically linking M2e repeat to the engineered H3 stalk domain with stabilizing HA1 N- and C-terminal region and point mutations |
NM2e@DDAB/PLA nanovaccine |
Chinese Academy of Sciences (China) | Non-VLP nanoparticles | Preclinical | Fusion protein expressing the extracellular domain of matrix 2 (M2e) and nucleoprotein, NM2e, adjuvanted with a cationic solid lipid nanoadjuvant fabricated using poly(lactic acid) (PLA) and dimethyl-dioctadecyl-ammonium bromide (DDAB), to generate an NM2e@DDAB/PLA nanovaccine (Nv). |
CTA1-3M2e-DD (FPM2e) |
University of Gothenburg (Sweden), Ghent University (Belgium) | Non-VLP nanoparticles | Preclinical | Combined M2e-based fusion protein with a cholera toxin-derived adjuvant (CTA1-DD) and lipid nanoparticles; aimed at enhancing anti-M2e antibodies and CD4+ T cell responses. |
rM2e-ΔPly |
Chongqing Medical University (China) | Recombinant proteins | Preclinical | A novel rM2e-ΔPly protein containing multiple M2e originated from different species of IAV expressed in Escherichia coli (E. coli) |
IA-SNBs |
NIAID (US) | Non-VLP nanoparticles | Preclinical | HA complexes arranged as lipid discs with multiple trimeric HAs displayed along the perimeter, termed spike nanobicelles (SNB), used to synthesize in vitro assembled spiked nanobicelles (IA-SNB) from a classical 1934 H1N1 influenza virus. |
BP26-M2e nanobarrels |
Korea Advanced Institute of Science and Technology (Korea) | Non-VLP nanoparticles | Preclinical | Engineered monomeric BP26 monomers bearing an antigen aimed at promoting antigen-specific antibody production. |
E10 nanobody |
Chinese Academy of Agricultural Sciences (China), University of Gothenburg (Sweden) | Non-VLP nanoparticles | Preclinical | Peptide based vaccine including E10, a hemagglutinin (HA)-specific nanobody that exhibits broad-spectrum binding, cross-group neutralization and in vivo protection across various influenza A subtypes. E10 specifically targets an epitope on HA head which is part of the conserved lateral patch and is highly immunodominant upon H7 infection. |
Reassortant LAIV with modified NS-1 and NP |
Institute of Experimental Medicine (Russia) | Influenza virus-based | Preclinical | Reassortant LAIV expressing modified NP and NS1 genes aimed at inducing a robust T-cell response |
ctLAIV |
Yonsei University (South Korea) | Influenza virus-based | Preclinical | Caspase-triggered live attenuated influenza vaccine (ctLAIV), which is self-attenuated by the host caspase-dependent cleavage of internal viral proteins. |
Inverted HA VLP |
CIVICs, NIAID (US), Georgia Institute of Technology (US), Icahn School of Medicine at Mount Sinai (US) | Virus-like particles (VLP) | Preclinical | A VLP that displays multiple copies of an antigen binding fragment (Fab) which recognizes the apex of the HA head causing the subsequent binding of HA to result in its presentation in an inverted orientation. |
Human adenovirus type 5 (HAdV-5)-vectored N1CC |
University of Nebraska−Lincoln (US) | Virus-vectored | Preclinical | A synthetic centralized consensus (CC) neuraminidase (NA) type 1 (N1CC) vaccine based on ancestral N1 sequences and delivered using a human adenovirus type 5 vector |
B60-Stem-8071 |
Xiamen University (China) | Recombinant proteins | Preclinical |
An HA stem vaccine grafted with an epitope of broadly neutralizing antibodies CR8071 to stabilize the stem HA domain |
BP-NP366/PA224 |
University of Melbourne (Australia), Griffith University (Australia) | Non-VLP nanoparticles | Preclinical | Endotoxin-free production strain of E. coli bioengineered to assemble biopolymer particles (BPs) coated with conserved influenza antigens (BP-NP366/PA224). |
IAV-nanovax |
University of Iowa (US), Iowa State University (US) | Non-VLP nanoparticles | Preclinical | Combination nanovaccine platform based on pentablock copolymer micelles and polyanhydride nanoparticles, incorporating the hemagglutinin (HA) and nucleoprotein (NP) antigens from H1N1; aimed at boosting cell-mediated immune responses. Status: Active |
Self assembling peptides displaying M2e and HA2 |
Russian Academy of Sciences (Russia) | Non-VLP nanoparticles | Preclinical | Self-assembling nanoparticles displaying M2e and HA stalk epitopes aimed at inducing humoral and T-cell responses |
NA-F2A-HA mRNA-LNP |
Duke University (US) | Nucleic acid-based | Preclinical | An mRNA vaccine platform that delivers NA and HA as a single open reading frame (ORF) to enable expression of multiple unmodified antigens from a single mRNA, using a unique glycoprotein organization with an artificial furin cleavage site and 2A ribosome-skipping sequences. |
N1-I COBRA NA antigen |
CIVICs, NIAID (US), Georgia State University (US) | Recombinant proteins | Preclinical | COBRA (computationally optimized broadly reactive antigens) generated N1-I NA vaccine designed to cross react with avian, swine and human influenza viruses of N1 NA subtype. |
HA-VLP-Cyt |
Georgia State University (US) | Virus-like particles (VLP) | Preclinical | Cytokine-adjuvanted influenza hemagglutinin virus-like particles (HA-VLP) vaccine aimed at inducing cellular and humoral immunity |
Recombinant HA proteins |
University of Wisconsin (US) | Recombinant proteins | Preclinical | Novel vaccine strategy involving introducing mutations into HA at amino acid positions at which Victoria- and Yamagata-lineage viruses differ, and selecting mutants that shared antigenic characteristics of both lineages, leading to the generation of ‘hybrid’ vaccine viruses with the potential to protect against both lineages. |
LAIV+4M2e |
Institute of Experimental Medicine (Russia) | Influenza virus-based | Preclinical | Recombinant LAIV expressing additional 4 M2e tandem repeats (4M2e); aimed at enhancing M2e-mediated cross-protection against heterologous viruses. |
Ad-5-H1 |
Icahn School of Medicine at Mount Sinai (US), University of Maryland (US) | Virus-vectored | Preclinical | Non-replicating adenoviral (Ad) vector, encoding a secreted form of H1 HA, aimed at eliciting cross-reactive stalk-mediated cellular and humoral immunity and protection. |
Self-assembled protein nanocages (SAPNs) |
Georgia Institute of Technology (US) | Non-VLP nanoparticles | Preclinical | A broadly cross-reactive influenza vaccine developed by functionalizing self-assembled protein nanocages (SAPNs) with multiple copies of the hemagglutinin stalk on the outer surface and matrix protein 2 ectodomain on the inner surface |
HMP-NP |
Northwest A&F University (China) | Non-VLP nanoparticles | Preclinical | Ferritin-based influenza nanoparticle vaccine that displays a multi-antigen targets on the surface of Helicobacter pylori ferritin, which consists of the ectodomain of HA and three tandem highly conserved influenza M1 epitopes fused with the universal helper T-cell epitope PADRE |
SpyTagged noro-VLP |
Tampere University (Finland) | Virus-like particles (VLP) | Preclinical | Uses a modular vaccine platform based on the noro-VLP, fused with highly conserved antigens, the ectodomain of M2e protein and a minimized stem-fragment of HA. |
Self amplifying mRNA |
University of Minnesota (US) | Nucleic acid-based | Preclinical | Self-amplifying mRNA vaccine encoding the influenza A virus nucleoprotein that is encapsulated in modified dendron-based nanoparticles. |
COBRA HA-encoding mRNA |
CIVICs, NIAID (US), University of Georgia (US) | Nucleic acid-based | Preclinical | mRNA encoding H1 and H3 COBRA hemagglutinins (HA) or wild-type (WT) influenza HAs encapsulated in lipid nanoparticles (LNPs) |
Ace-DEX microparticle |
University of North Carolina (US) | Non-VLP nanoparticles | Preclinical | M2e- and cyclic GMP-AMP (cGAMP)-encapsulated acetylated dextran (Ace-DEX) microparticles (MP); antigen-adjuvant combination is aimed at activation of humoral and cellular responses. |
ΔNS1 virus |
CIVICs, NIAID (US), Icahn School of Medicine at Mount Sinai (US) | Influenza virus-based | Preclinical | Live attenuated Influenza A virus lacking the NS1 gene (ΔNS1) expressing cHAs corresponding to the head of H8 and the stalk of H1 (cH8/1) and to the head of H11 and the stalk of H1 (cH11/1); administered intranasally aimed at inducing an innate antiviral response |
ChAdOx2-NPM1-NA2 and MVA-NPM1NA2 |
Pirbright Institute (UK) | Virus-vectored | Preclinical | Aerosol immunization with viral vectored vaccines (ChAdOx2 and MVA) expressing matrix (M1) and nucleoprotein (NP) |
LHNVD-105/110 |
Longhorn Vaccines and Diagnostics (US) | Recombinant proteins | Preclinical | An unconjugated multiepitope composite peptide vaccine including conserved peptides from the HA, NA, and matrix (M1, M2, M2e) proteins combined with a T-cell epitope, formulated with the ALFQ (Army liposomal formulation with QS21) adjuvant. Rikhi 2025, Rikhi 2025, Rikhi 2023 (PMID: 37766144), Kroscher 2022, Sei 2021 (PMID: 34202178), Sei 2018, News Story 11-5-2024, Press Release 4-27-2024, Press Release 9-27-2023, Press Release 10-24-2022, Patent: Composite antigenic sequences and vaccines, Developer Website: Longhorn Vaccines and Diagnostics
|
M2e/CpG-ODN/TMC |
Agricultural Research, Education and Extension Organization (Iran) | Non-VLP nanoparticles | Preclinical | Nasal vaccination with the M2e/CpG-ODN antigen encapsulated in N-Trimethyl Chitosan (TMC) nanoparticles |
DIOSvax-H5inter Homotypic Nanocages |
DIOSynVax (UK) | Non-VLP nanoparticles | Preclinical | An optimised H5 HA nanocage vaccine developed by combining a novel computationally designed vaccine antigen using Digitally Immune Optimised Synthetic Vaccine (DIOSynVax) antigen design technology, with the Plug-And-Display SpyTag003/SpyCatcher003-mi3 nanoassembly platform. The novel, recombinant H5 immunogen with antigenic determinants representative across different clades of the H5 subtype, DIOSvax-H5inter , is generated as a self-assembling Homotypic Nanocage. |
H1, HA COBRA IIV |
CIVICs, NIAID (US), Cleveland Clinic (US), University of Georgia (US) | Influenza virus-based | Preclinical | Reassortant influenza viruses expressing H1 and H3 computationally optimized broadly reactive antigens (COBRA) hemagglutinin (HA) Chen 2025 (PMID: 40186991), Shi 2025 (PMID: 39982912), Shi 2024 (PMID: 38826029), Nagashima 2024 (PMID: 38810648), Editors 2024 (PMID: 38198500), Dzimianski 2023 (PMID: 37185989), Nagashima 2023 (PMID: 36851561), Ross 2022 (PMID: 36016202), Abbadi 2022 (PMID: 35916534), Nagashima 2022 (PMID: 35697384), Allen 2022 (PMID: 35289635), Huang 2021 (PMID: 34358209), Sautto 2021 (PMID: 33853960), Sautto 2018 (PMID: 31022693), Allen 2018 (PMID: 30265682)
|
rAd-HA2 |
Health Canada (Canada), University of Ottawa (Canada) | Virus-vectored | Preclinical | Recombinant adenovirus vaccine (rAd) carrying a synthetic HA2 representing the consensus sequence of all influenza B virus HAs |
Self-assembling protein nanoparticles (SApNPs) |
Scripps Research Institute (US) | Non-VLP nanoparticles | Preclinical | Single-component self-assembling protein nanoparticles (SApNPs) presenting the conserved extracellular domain of matrix protein 2 (M2e) |
OMV-M2e |
Cornell University (US) | Non-VLP nanoparticles | Preclinical | Recombinant TLR2-active outer membrane vesicles (OMVs) that carry sequences of the M2e protein (OMV-M2e) |
cVLPs |
University of Copenhagen (Denmark), Scripps Research Institute (US) | Virus-like particles (VLP) | Preclinical | Recombinant vaccine antigens (HAstem or rNA) displayed on the surface of rigid capsid-based virus-like particles (cVLP). (formerly: CLP-HAstem) |
NA2 VLP |
Auburn University (US), Emory-UGA CEIRS (US) | Virus-like particles (VLP) | Preclinical | Vaccine containing the NA protein from A/Perth/16/2009 (H3N2) and the matrix 1 (M1) protein from A/MI/73/2015, formulated with a water-in-oil-in-water adjuvant |
mHAs |
Chinese Academy of Sciences (China) | Nucleic acid-based | Preclinical | mRNA vaccine (mHAs) encoding the HA stem antigen of the influenza A (H1N1) virus. |
M2e nanovaccine |
University of Quebec at Montreal (Canada) | Non-VLP nanoparticles | Preclinical | Multicomponent nanovaccine based on a fragment (R4R5) of the Curli-specific gene A (CsgA) protein; composed of cross-β-sheet nanofilaments exposing the conserved M2e epitope from the influenza virus; aimed at inducing a protective M2e-specific immune response. |
Prime and HA |
Yale University (US) | Recombinant proteins | Preclinical | Intranasal recombinant HA protein booster; used following intramuscular HA-encoding mRNA-LNP prime vaccine to elicit protective mucosal immune responses and confer sterilizing immunity against influenza virus infection. |
rNA antigens |
Ghent University (Belgium), Sanofi (France) | Recombinant proteins | Preclinical | Computationally engineered consensus NA sequences forming 3 recombinant NA proteins. |
pEx 4M2e |
Slovak Academy of Science (Slovak Republic) | Nucleic acid-based | Preclinical | DNA vaccine aimed at inducing an anti-M2e immune response by inserting the sequence for truncated NS1 protein followed by 4xM2e into the expression vector pEx (PTriEx-4). |
mRNA-Flu |
National Institute for Public Health and the Environment (Netherlands) | Nucleic acid-based | Preclinical | Nucleoside-modified mRNA-LNP encoding three conserved internal proteins of H1N1 influenza virus, NP, M1, and PB1 |
Mosaic nucleoprotein (MNP) |
University of Wisconsin (US) | Recombinant proteins | Preclinical | A mosaic nucleoprotein (MNP) created by synthesizing a sequence that maximized the representation of 9-mer epitopes from 7422 NP sequences across human, swine, and avian IAVs; administered intranasally with combination adjuvant consisting of Adjuplex (ADJ; carbomer-based adjuvant) and glucopyranosyl lipid A (GLA; TLR-4 agonist). |
S-FLU and CLEARFLU |
University of Oxford (UK), University of Melbourne (Australia) | Influenza virus-based | Preclinical | Single-cycle viruses that are either produced by the inactivation of the hemagglutinin signal sequence, generating a viral RNA called S-HA (S-FLU), or a derivative of S-FLU that expresses a stabilized non-fusogenic hemagglutinin (CLEARFLU); aimed at inducing T cell responses when administered to the lung. |
MVA-vectored vaccines |
Emergent BioSolutions (US) | Virus-vectored | Preclinical | MVA-vectored vaccines expressing HA, NP, M1, M2, repeats of M2e or as tandem repeats (METR), and M2e with transmembrane region and cytoplasmic loop (M2eTML) as single antigens that were delivered separately or in combination. |
COBRA HA and NA proteins |
University of Georgia (US) | Recombinant proteins | Preclinical | Multivalent COBRA (computationally optimized broadly reactive antigens) HA and NA immunogens (N1 and N2) designed to cross react with several IAV strains, combined with novel immunostimulatory adjuvants, such as: Advax-SMTM, a novel adjuvant comprising inulin polysaccharide and CpG55.2, a TLR9 agonist, c-di-AMP adjuvant, or Infectimune®, a cationic lipid nanoparticle adjuvant. |
Whole influenza virus particle vaccine |
Hokkaido University (Japan) | Influenza virus-based | Preclinical | Good manufacturing practice (GMP) grade monovalent or quadrivalent inactivated whole influenza virus particle vaccine (WPV) formulations |
COBRA-VLP |
CIVICs, NIAID (US), University of Georgia (US), Cleveland Clinic (US) | Virus-like particles (VLP) | Preclinical | VLP constructs expressing COBRA (computationally optimized broadly reactive antigens) for HA or NA (specifically N2 NA); aimed at eliciting high-titer broadly cross-reactive neutralizing antibodies to multiple HA epitopes on antigenically distinct influenza viruses. Zhang 2024 (PMID: 39291424), Ge 2024 (PMID: 39079813), Nagashima 2024 (PMID: 38810648), Carlock 2023 (PMID: 37741893), Ge 2023 (PMID: 36680243), Moise 2022 (PMID: 35704783), Nunez 2021 (PMID: 34832509), Allen 2021 (PMID: 34475872), Reneer 2021 (PMID: 33692193), Allen 2021 (PMID: 33654128), Reneer 2020 (PMID: 33115871), Huang 2020 (PMID: 31852790), Nunez 2020 (PMID: 31733946), Sautto 2020 (PMID: 31811019), Ross 2019 (PMID: 30905528), Skarlupka 2019 (PMID: 31448974), Bar-Peled 2019 (PMID: 31481254), Allen 2017 (PMID: 28789850), Wong 2017 (PMID: 28978710), Carter 2017 (PMID: 28978709), Carter 2016 (PMID: 26912624), Crevar 2015 (PMID: 25671661), Giles 2012 (PMID: 22190399), Giles 2011 (PMID: 21320540), Press Release 9-20-2023, Press release 7-14-2022, Developer presentation 2023
|
NA-Mi3 nanoparticles |
Utrecht University (Netherlands), Ghent University (Belgium) | Non-VLP nanoparticles | Preclinical | Soluble tetrameric NA antigens of the N1 and N2 subtypes conjugated to Mi3 self-assembling protein nanoparticles using the SpyTag-SpyCatcher system. |
VT-105 |
Versatope Therapeutics (US) | Non-VLP nanoparticles | Preclinical | Combines diverse variants of influenza strains displayed on a single nano-sized rOMV (recombinant outer membrane vesicle); VT-105 is based on the M2 protein; targets the virus-infected cell to engage cell-mediated immune responses against all influenza strains. |
Multi-epitope mRNA-based vaccines (MH, MH-T, and MH-TF) |
Key Laboratory of Jilin Province for Zoonosis Prevention and Control (China) | Nucleic acid-based | Preclinical | Self-assembled mRNA-based multi-epitope influenza vaccine, which combines three conserved antigens derived from the influenza A virus (M2 ion channel’s extracellular domain (M2e), the conserved epitope of located in HA2 of hemagglutinin (H1, H3, B), and HA1 of hemagglutinin) |
Mosaic and Chimeric HA |
Icahn School of Medicine at Mount Sinai (US) | Recombinant proteins | Preclinical | Novel constructs of recombinant mosaic and chimeric HA, expressed as soluble trimeric proteins; aimed at inducing broadly protective immune responses to influenza A and B strains. |
CapM2e+Advax-SM |
Vaxine (Australia) | Recombinant proteins | Preclinical | M2e antigen based vaccine formulated with Advax-SM adjuvant administered to mothers aimed at inducing passive maternal protection to newborns |
MAV-1 HA |
University of Liège (Belgium) | Virus-vectored | Preclinical | Recombinant mouse adenovirus (AdV) type 1 (MAV-1) expressing the HA of PR8, administered orally |
CHM-f nanoparticle |
Northwest A&F University (China), Chengdu NanoVAX Biotechnology (China) | Non-VLP nanoparticles | Preclinical | Ferritin-based influenza nanoparticle vaccine co-expressing the ectodomain of HA (H), three repeated M2e epitopes (M), and the M-cell-targeting ligand Co4B ©, which are fused in tandem to the N-terminus of ferritin (f), creating the CHM-f nanoparticle. Administered intranasally with or without the CpG IAMA-002 adjuvant. |
CDh-f nanoparticle |
Jilin University (China) | Non-VLP nanoparticles | Preclinical | The A helix (Ah) and CD helix (CDh) from the HA stem were fused with ferritin, individually, or in tandem, yielding Ah-f, CDh-f and (A + CD)h-f nanoparticles (NPs), produced through a prokaryotic expression system. |
AdC68-cHAs |
Tianjin Medical University (China), Fudan University (China) | Virus-vectored | Preclinical | Novel cHAs comprising two or three fuzed head domains from different subtypes grafted onto one stalk domain, designated as cH1-H3, cH1-H7, cH1-H3-H7, and cH1-H7-H3 |
Chimeric HA and M2 mRNA cocktail |
Chinese Academy of Medical Sciences (China) | Nucleic acid-based | Preclinical | mRNA vaccine encoding two novel chimeric HAs, cH5/1-BV and cH7/3, as well as the intact M2 (termed Fluaxe), to protect at least six influenza subtypes, including two circulating IAV group 1 (H1N1 and H5N1), two IAV group 2 (H3N2 and H7N9), and two IBV lineages (Victoria and Yamagata). In addition, HAs from two highly pathogenic avian influenza (HPAI), namely H5N1 and H7N9, were introduced to the mRNA-based vaccine to further combat the severe hazard of major poultry epizootics to human health |
HA trimers |
California Institute of Technology (US) | Non-VLP nanoparticles | Preclinical | Uses the SpyCatcher-SpyTag “plug and display” strategy to covalently couple trimeric HAs to symmetric particles with different numbers of attachments sites, resulting in mosaic particles displaying HA antigens derived from up to 8 strains of group 1 and group 2 influenza A viruses. |
3MCD-f nanovaccine |
Jilin University (China) | Non-VLP nanoparticles | Preclinical | Biepitope adjuvant-free, self-assembled influenza nanovaccine consisting of two conserved epitopes (M2e and CDhelix) |
Monovalent rNA |
Sanofi (France) | Recombinant proteins | Preclinical | A rNA monovalent protein vaccine candidate vaccine that uses tetramer conformation to enable stability for at least 24-months at refrigerated (5°C) storage. |
IAV NP mRNA/DDO268 |
Washington University (US) | Nucleic acid-based | Preclinical | Viral-derived oligonucleotides (DDO) adjuvanted mRNA vaccine encoding the IAV NP |
N2-MPP |
CIVICs, NIAID (US), Icahn School of Medicine at Mount Sinai (US) | Recombinant proteins | Preclinical | Recombinant influenza virus N1 neuraminidase vaccine candidate, N1-MPP, adjuvanted with CpG 1018, a TLR9 agonist, designed to contribute to the development of a broadly protective NA-based influenza virus vaccine candidate. Formerly N1-MPP and rNA. Hoxie 2024 (PMID: 39241354), McMahon 2023 (PMID: 37800945), Momont 2023 (PMID: 37258672), Strohmeier 2022 (PMID: 35869085), Roubidoux 2022 (PMID: 35446141), Tan 2022 (PMID: 34669506), Rajendran 2021 (PMID: 34451971), Oh 2021 (PMID: 34890255), Strohmeier 2021 (PMID: 34809451), Strohmeier 2021 (PMID: 33921722), McMahon 2020 (PMID: 32943267), McMahon 2019 (PMID: 31113896), Wohlbold 2015 (PMID: 25759506)
|
RSM2eFP spore vaccine |
Beijing Institute of Microbiology and Epidemiology (China) | Influenza virus-based | Preclinical | Recombinant influenza vaccine using Bacillus subtilis spores expressing M2e-FP protein (RSM2eFP) administered via aerosolized intratracheal inoculation (i.t.). |
5xM2e mRNA lipid nanoparticle |
Georgia State University (US) | Nucleic acid-based | Preclinical | Lipid nanoparticle (LNP)–encapsulated 5xM2e mRNA vaccine encoding the tandem repeat conserved ectodomain (M2e) of ion channel protein M2 derived from human, swine, and avian influenza A viruses. Administered alone or co-administered with an inactivated split vaccine. Research includes the development of an influenza B virus NA mRNA vaccine candidate, co-administered with conventional split influenza B vaccine at low doses, to induce cross-lineage protection. |
H1H3 VLPs |
Kyung Hee University (S Korea) | Virus-like particles (VLP) | Preclinical | Influenza VLPs co-expressing only IAV-derived hemagglutinin (HA) antigens H1 and H3, aimed at conferring cross-protection against IBVs (Formerly: H3N1M2e5x VLP) |
SCPs/pHAF |
Jilin University (China) | Non-VLP nanoparticles | Preclinical | Novel multi-epitope nanoantigenic DNA vaccine using a ferritin carrier that is engineered with HA gene fragments, along with ferritin and GCN4pII sequences, delivered using silica-coated calcium phosphate (SCPs) nanoparticles encapsulating influenza hemagglutinin plasmids (pHAF/pHAG) via polyethyleneimine adsorption as a novel vector to elicit potent T cell-mediated immunity. |
3M2e-rHF nanoparticle |
Chinese Academy of Sciences (China) | Non-VLP nanoparticles | Preclinical | Tandem copies of M2e (3M2e) displayed on ferritin nanoparticles (recombinant human heavy chain ferritin, rHF); intranasal administration; aimed at stimulating cross-protective immunity through M2e-specific IgG antibodies, T-cell immune responses, and mucosal secretory-IgA antibodies. |
NA-M2e VLP |
Georgia State University (US) | Virus-like particles (VLP) | Preclinical | A virus-like particle vaccine containing multi-subtype NA and M2e repeat (NA-M2e) combined with inactivated split seasonal influenza vaccine, aimed at enhancing immunity against homologous and heterologous influenza viruses. (Formerly: m-cNA-M2e VLP) |
Quadrivalent VLPs |
National Health Research Institutes (Taiwan) | Virus-like particles (VLP) | Preclinical | An insect cell-based baculovirus expression system used to generate rBVs bearing influenza HA, NA, and M1 genes from four seasonal influenza vaccine strains which are used to produce insect cell-based VLPs as quadrivalent seasonal influenza vaccine candidates |
ta-RNA, sa-RNA |
BioNTech (Germany), Johannes Gutenberg University Mainz (Germany) | Nucleic acid-based | Preclinical | RNA vaccine approach based on a novel split-vector system using trans-amplifying RNA (taRNA) or self-amplifying (saRNA) encoding HA antigen. |
PR8HA-VLP |
CIVICs, NIAID (US), University of Wisconsin (US), Georgia Institute of Technology (US) | Virus-like particles (VLP) | Preclinical | VLP-based vaccine presenting multiple copies of the HA from A/Puerto Rico/8/1934 (PR8HA-VLP) |
Mosaic HA-based whole inactivated virus |
Icahn School of Medicine at Mount Sinai (US) | Influenza virus-based | Preclinical | Activated influenza B viruses displaying mosaic HA (mHA) proteins to redirect the immune response towards the immuno-subdominant conserved epitopes of the HA. |
3M2e-T4 nanoparticle |
Huazhong Agricultural University (China) | Non-VLP nanoparticles | Preclinical | Insertion of Flu viral M2e into phage T4 genome through fusion to Soc (Small Outer Capsid protein) generated a recombinant phage, and the Soc-M2e proteins self-assembled onto phage capsids to form 3M2e-T4 nanoparticles during propagation of T4 in E. coli. |
LPP-HNH mRNA |
China CDC (China) | Nucleic acid-based | Preclinical | A multi-antigen influenza mRNA vaccine, LPP-HNH mRNA, coding headless hemagglutinin (HA stem) and neuraminidase (NA) with three optimized sequences (HNH-ORI, HNH-E1 or HNH-E2) and delivered by lipopolyplex (LPP). |
rAd/NP + rAd/HA-M2e |
Ewha Womans University (Korea) | Virus-vectored | Preclinical | Recombinant adenovirus-based vaccine that expresses influenza NP, HA, and M2e in a mixture of rAd/NP and rAd/HA-M2e administered intranasally or intramuscularly. |
Clec9A-M2e |
National University of Singapore (Singapore), Monash University (Australia) | Recombinant proteins | Preclinical | Targeting strategy that shuttles M2e to a specific dendritic cell subset (cDC1) by engineering a recombinant anti-Clec9A monoclonal antibody fused at each of its heavy chains with three copies of M2e |
RAM-IGIP |
University of Georgia (US) | Influenza virus-based | Preclinical | Attenuated MLV (modified live virus) vaccine, built by rearranging FLUAV genome segments and incorporating the IgA-inducing protein |
Double-layered protein nanoparticles |
Georgia State University (US) | Non-VLP nanoparticles | Preclinical | Layered protein nanoparticles expressing multivalent conserved antigens (M2e, NP, HA stem domains); conjugated with truncated flagellin (tFliC); aimed at inducing broadly cross-protective immune responses. Status: Active Kim 2024 (PMID: 39240547), Wang 2023 (PMID: 36265560), Song 2022 (PMID: 35810540), Dong 2022 (PMID: 35084819), Dong 2022, Ma 2021 (PMID: 34743020), Wang 2021 (PMID: 34179728), Tang 2020 (PMID: 33114336), Wang 2020 (PMID: 31840437), Deng 2018 (PMID: 30065113), Deng 2018 (PMID: 30394725), Wang 2018 (PMID: 30365905), Deng 2018 (PMID: 29367723), Chang 2018 (PMID: 30092060), Deng 2017 (PMID: 28622575), Wang 2014 (PMID: 23988715), Press Release 7-1-2019, NIH Funding
|
rVSV-EΔM-tM2e |
University of Manitoba (Canada) | Virus-vectored | Preclinical | rVSV-based vaccine candidates expressing the ectodomain of influenza matrix protein (M2e) and/or conserved hemagglutinin stalk regions (HA stalk) fused with the DC-targeting domain of EboGP (E1M) to generate E1M-tM2e or E1M-HM2e, which is UV-inactivated.
|
mRNA LNP prime and intranasal PHC boost |
Georgia State University (US) | Nucleic acid-based | Preclinical | Heterologous sequential mRNA LNP priming followed by intranasal protein nanoparticle boosting immunization to confer optimal cross-protection against antigenically drifted and shifted influenza strains. See also Georgia State University’s, HA/GP nanoparticles and cGAMP-adjuvanted multivalent mRNA vaccines |
Self-assembled multiepitope nanoparticles (MHF) |
Jilin University (China) | Non-VLP nanoparticles | Preclinical | Multiepitope nanovaccine, MHF, made up of conserved linear epitopes of HA2, M2e, and NP fused to either three surface loops on the P domain, or to ferritin. (Formerly: HMN-PP) |
rTET-NA |
Sanofi (France) | Recombinant proteins | Preclinical | Soluble recombinant NAs produced from a number of subtypes by fusion of the globular head domain with the tetrabrachion tetramerization domain (rTET-NA), added to a quadrivalent HA-based influenza vaccine |
Intranasal NLP:NP |
University of Rochester Medical Center (US) | Non-VLP nanoparticles | Preclinical | Self-assembling nanolipoprotein particle linked to NP with an adjuvant |
MVA-NP |
German Center of Infection Research (DZIF) (Germany) | Virus-vectored | Preclinical | Recombinant MVA candidate vaccines that deliver the highly conserved internal nucleoprotein (NP) of IAV under the transcriptional control of five newly designed chimeric poxviral promoters to further increase the immunogenic properties of the recombinant viruses (MVA-NP) |
TMV-HA-con |
University of Nebraska−Lincoln (US) | Non-VLP nanoparticles | Preclinical | Plant-made vaccines comprising centralized consensus influenza hemagglutinin (HA-con) proteins (H1 and H3 subtypes) conjugated to a modified plant virus, tobacco mosaic virus (TMV) nanoparticle (TMV-HA-con). |
A/NP+M2-rAd |
Food and Drug Administration (US) | Virus-vectored | Preclinical | Replication-deficient recombinant adenovirus-5 (rAd) vectors expressing conserved antigens NP and M2. |
AdC68-CR9114 |
Fudan University (China) | Virus-vectored | Preclinical | Chimpanzee adenoviral vector, AdC68, expressing CR9114, a broadly neutralizing monoclonal antibody isolated form the peripheral blood mononuclear cells of healthy donors; CR9114 targets different types of influenza viruses. |
COBRA H1 HA |
University of North Carolina (US), University of Georgia (US) | Recombinant proteins | Preclinical | COBRA HA vaccine coadministered intranasally with a novel adjuvant. Adjuvants include PEI-Ox-DEX hydrogel, M7-CpG, and cGAMP MPs |
HA-SAV |
Yonsei University (South Korea) | Non-VLP nanoparticles | Preclinical | A self-assembled vaccine (SAV) platform comprising antigen-polymer conjugates to elicit enhanced immune responses against pathogen |
PapMV-sM2e nanoparticles |
Laval University (Canada) | Non-VLP nanoparticles | Preclinical |
Two types of PapMV (papaya mosaic virus) nanoparticles harboring the M2e and NP antigens; aimed at inducing broadly protective immune responses. |
Deglycosylated modified HA |
Xiamen University (China) | Recombinant proteins | Preclinical |
Deglycosylated modified HA proteins from H3N2 with various lengths of glycans administered intramuscularly |
CyCMV/Flu |
Oregon Health & Science University (US) | Virus-vectored | Preclinical | Cytomegalovirus (CMV)-vectored vaccine (CyCMV) expressing conserved internal influenza antigens (M1, NP, and PB1), aimed at inducing lung-resident influenza-specific CD4+ T cells to provide long-lived heterosubtypic protection. |
Polyvalent DNA vaccine |
Statens Serum Institut (Denmark) | Nucleic acid-based | Preclinical | Needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine encoding HA and NA proteins derived from less glycosylated pandemic H1N1 (2009) and H3N2 (1968) virus strains and nucleoprotein (NP) and matrix proteins (M1 and M2) from a different pandemic H1N1 (1918) strain. |
cVLPs |
Jiaxing University (China) | Virus-like particles (VLP) | Preclinical | The conserved stalk domain and 4M2e co-anchored to the surface particles to generate chimeric influenza VLPs aimed at inducing humoral and mucosal immune responses. |
M2 peptide micelles |
University of Missouri (US) | Non-VLP nanoparticles | Preclinical | Immunostimulatory micellar nanoparticles generated from M22–16 peptides by lipid conjugation |
3M2e-HA2-NP chimeric subunit |
Pasteur Institute of Iran (Iran) | Recombinant proteins | Preclinical | Recombinant chimeric protein 3M2e-HA2-NP containing conserved regions of M2e, HA, and NP derived from influenza A virus. |
Trimeric HA-Fc |
University of Maryland (US) | Recombinant proteins | Preclinical | Monomeric IgG Fc fused to influenza virus hemagglutinin (HA) Ag with a trimerization domain |
Scrambled HA (scrHA) |
CIVICs, NIAID (US), University of Wisconsin (US) | Recombinant proteins | Preclinical | An H3 HA vaccine antigen with various amino acids at immunodominant epitopes of the HA head domain. |
Ferritin-HA |
Shanghai Institute of Biological Products (China) | Non-VLP nanoparticles | Preclinical | Recombinant, self-assembling ferritin nanoparticle that presents the extracellular domain of the influenza hemagglutinin antigen on its surface, designated as ferritin-HA |
LBL HA-4M2e NPs |
Georgia Institute of Technology (US) | Non-VLP nanoparticles | Preclinical | Chimeric tetramer M2e antigen nanoparticles conjugated to HA antigen, then coated layer-by-layer (LBL) with alternating layers of cationic chitosan and anionic CpG adjuvants, administered intranasally |
rMVA-k1-k2 |
Federal Medical-Biological Agency (Russia) | Virus-vectored | Preclinical | Epitope-based vaccine against influenza based on modified vaccinia Ankara (MVA) vector and using an algorithm to select epitopes from conserved fragments of the NP, M1 and HA proteins of influenza A and B |
Hexaplex liposomes |
State University of New York at Buffalo (US) | Non-VLP nanoparticles | Preclinical | Recombinant HA and NA multimeric proteins derived from three influenza serotypes, H1N1, H3N2, and type B, are surface displayed on nanoliposomes co-loaded with immunostimulatory adjuvants, generating "hexaplex" particles |
HA-liposomes |
Monash University (Australia) | Non-VLP nanoparticles | Preclinical | Production of lipid nanoparticle subunit vaccines with HA immunogens functionalized on the surface of the liposomes; uses advanced microfluidic mixing technology (NanoAssemblr) to enable rapid preparation of liposomal vaccines with increased concentrations of HA antigens on the liposome surface; aimed eliciting HA-specific B cell and follicular helper T cell immune responses. |
HA-F DNA vaccine |
Jilin University (China) | Nucleic acid-based | Preclinical | A DNA vaccine designed by fusing influenza virus HA with self-assembled ferritin nanoparticles aimed at providing robust immunogenicity, high protective efficacy and being an effective vaccine with rapid production |
rAAV-COBRA |
St Jude Children’s Research Hospital (US) | Virus-vectored | Preclinical | Recombinant adenovirus-associated virus (rAAV) vector expressing a computationally optimized broadly reactive antigen (COBRA)-derived influenza H1 hemagglutinin (HA) with modestly enriched CpG motifs to evoke a robust and long-lasting immune response |
Multiple HA-DNA |
University of Oslo (Norway) | Nucleic acid-based | Preclinical | DNA-encoded vaccine proteins targeting APCs; uses either the ectodomain of NA as an antigen, or HA genes from 16 different HAs representing nearly all of the different HA subtypes (except H1 and H7) and inserts them into a DNA vaccine format; aimed at inducing NA immunity and delivery of the HA protein antigens to MHC class II molecules on APCs. |
mRNA LNP vaccine encoding a Y2 COBRA HA immunogen |
CIVICs, NIAID (US), University of North Carolina (US), University of Georgia (US) | Nucleic acid-based | Preclinical | mRNA LNP vaccine encoding a Y2 COBRA HA immunogen, which is based on a full length HA consensus sequence; adjuvanted with acetlyated dextran microparticles (Ace-DEX MPs) encapsulating a STING agonist. |
M2e based recombinant fusion proteins |
Russian Ministry of Health (Russia) | Recombinant proteins | Preclinical | Recombinant plant-produced protein (Flg4M2eHA2-1) based on the combination of 4 tandem copies of M2e and conserved fragments of HA2, fused to bacterial flagellin containing CD8+ epitopes of NP as an adjuvant for mucosal immunization; administered intranasally. |
M2e-CRM197 conjugates |
Chinese Academy of Sciences (China) | Recombinant proteins | Preclinical | Dual-site specific conjugation of M2e peptide with the CRM197 carrier protein under denaturation. |
Nano-Flu (tNIV) |
Novavax (US), Emergent BioSolutions (US) | Non-VLP nanoparticles | Phase 3 | Recombinant Spodoptera frugiperda (Sf9) insect cell or baculovirus system-derived, trivalent haemagglutinin (HA) nanoparticle influenza vaccine (NIV), formulated with a saponin-based adjuvant, Matrix-M™ (tNIV). Goal Vincent 2024 (PMID: 39597746), Shinde 2022 (PMID: 34563277), Isakova-Sivak 2022 (PMID: 34563276), Abbasi 2021 (PMID: 34751731), Shinde 2021 (PMID: 33146720), Portnoff 2020 (PMID: 32098409), Shinde 2018 (PMID: 29897849), Smith 2017 (PMID: 28844407), NCT06485752 (P3- Withdrawn), NCT04120194 (P3), NCT03658629 (P2- Terminated), NCT03293498 (P1/2), Press Release 6-11-2025, Press Release 12-10-2024, Press Release 11-11-2024, Press Release 10-16-2024, Press Release 8-8-2024, Press Release 5-9-2023, Press Release 9-23-2021, Press Release 5-10-2021, Press Release 10-13-2020, Press Release 5-6-2020, Press Release 3-24-2020, Press Release 2-25-2020, Press Release 1-15-2020, News Story 5-9-2023, Developer website: Novavax, Developer website: Emergent BioSolutions
|
Multimeric-001 (M-001) |
BiondVax Pharmaceuticals (Israel) | Recombinant proteins | Phase 3 | A single recombinant protein of 9 conserved M1, NP, and HA epitopes; aimed at inducing T cell responses and enhanced B-cell responses to circulating and novel strains. Goal Atmar 2023 (PMID: 36941155), Phillipson 2019 (PMID: 35174313), Lowell 2017 (PMID: 28065476), Van Doorn 2017 (PMID: 28296763), Astmon 2014 (PMID: 25173483), Gottlieb 2014 (PMID: 25172355), Astmon 2012 (PMID: 22318394), NCT03450915 (P3), NCT03058692 (P2), NCT02691130 (P2b), NCT02293317 (P2), NCT01419925 (P2), NCT01146119 (P2), NCT01010737 (P1/2), NCT00877448 (P1/2), Press Release 10-23-2020, Developer website: Now known as Scinai Immunotherapeutics
|
Quadrivalent VLP (QVLP) |
Medicago (Canada) | Virus-like particles (VLP) | Phase 3 | Nicotiana benthamiana plant-derived (Proficia®) HA-bearing quadrivalent virus-like particle (QVLP); aimed at stimulating antibody and cellular immune responses. Goal Alvarez 2022 (PMID: 35750356), Hendin 2022 (PMID: 35410323), Ward 2021 (PMID: 33581920), Ward 2020 (PMID: 33065035), Tregoning 2020 (PMID: 33065033), Pillet 2019 (PMID: 31166987), Won 2018 (PMID: 30448064), Pillet 2016 (PMID: 26987887), Press Release 2-3-2023, Press Release 10-1-2019, Press Release 06-2018, NCT03739112 / EudraCT 2018-001894-26 (P3), NCT03301051 / EudraCT 2017-001239-38 (P3), NCT03321968 (P3), NCT04622592 (P1/2), NCT02831751 (P2), NCT02768805 (P2), NCT02233816 (P2), NCT02236052 (P2), NCT01991587 (P1/2), Developer website
|
CIC Vaccine |
Novavax (US) | Non-VLP nanoparticles | Phase 3 | Combination SARS-CoV-2 (COVID-19) and influenza vaccine that uses full-length, stabilized recombinant spike (rS) protein of the SARS-CoV-2 virus, and 4 wild-type recombinant Hemagglutinin (rHA) proteins from the influenza virus, as antigens. Goal Massare 2021, NCT06482359 (P3- Withdrawn), NCT06291857 (P3), NCT05519839 (P2), NCT04961541 (P1/2), Press Release 6-11-2025, Press Release 5-8-2025, Press Release 12-10-2024, Press Release 11-11-2024, Press Release 10-16-2024, Press Release 8-8-2024, Press Release 5-10-2024, Press Release 5-10-2024, Press Release 4-1-2024, Press Release 5-9-2023, Press Release 12-30-2022, Press Release 10-13-2022, Press Release 4-20-2022, Press Release 9-8-2021, Press Release 6-14-2021, Press Release 5-10-2021, News Story 5-9-2023, Novavax presentation Sep 2024, Novavax presentation Mar 2024, Novavax presentation Jan 2024, Novavax presentation Aug 2023, Novavax Presentation Apr 2022, Developer Website: Novavax
|
mRNA-1083 |
Moderna (US) | Nucleic acid-based | Phase 3 | Combination SARS-CoV-2 (COVID-19) and influenza vaccine. Single dose mRNA vaccine encoding for the COVID-19 spike protein and flu HA glycoproteins of 4 flu strains. mRNA-1083 comprises components of mRNA-1010, Moderna's next-generation vaccine candidate for seasonal influenza, and mRNA-1283, Moderna's next-generation COVID-19 vaccine candidate. (Formerly: mRNA-1073 and mRNA-1083) Goal Akingbola 2025 (PMID: 40413212), Rudman Spergel 2025 (PMID: 40332892), Rudman Spergel 2025 (PMID: 40102593), NCT06694389 (P3), NCT06097273 (P3), NCT06864143 (P2), NCT06508320 (P2), NCT05827926 (P1/2), NCT05375838 (P1/2), Press release 5-21-2025, News story 5-7-2025, News story 5-2-2025, News story 5-1-2025, Press Release 5-1-2025, Press Release 2-14-2025, Press release 1-13-2025, Press release 8-1-2024, Press Release 6-10-2024, Press Release 5-2-2024, Press Release 3-27-2024, Press Release 1-8-2024, News Story 10-26-2023, Press Release 10-24-2023, Press release 10-4-2023, Press Release 9-13-2023, Press Release 5-4-2023, Press Release 4-11-2023, Press Release 2-16-2023, Press Release 9-8-2022, Press Release 6-7-2022, Press Release 3-24-2022, Press Release 12-10-2021, News Story 9-10-2021, Press Release 9-9-2021, Moderna Presentation May 2025, Moderna Presentation Jan 2025, Moderna Presentation Sep 2024, Moderna Presentation Jan 2024, Moderna Presentation Nov 2021, Developer Website: Moderna
|
Modified mRNA vaccine |
Pfizer (US) | Nucleic acid-based | Phase 3 | Next generation mRNA seasonal influenza vaccine encoding WHO recommended strain Goal Branche 2025 (PMID: 40333267), Hauguel 2024, Dolgin 2021 (PMID: 34635829), Abbasi 2021 (PMID: 34751730), Press Release 8-16-2024, Press Release 10-31-2023, Press Release 9-14-2022, Press Release 9-14-2022, Press Release 9-27-2021, Press Release 8-16-2018, NCT05540522 (P3), NCT06436703 (P2), ISRCTN13559330 (P2a), ISRCTN13789612 (P2a), NCT05052697 (P1/2), Pfizer Second Quarter 2022 Earnings Teleconference, Developer website: Pfizer
|
modRNA-based combination |
Pfizer (US), BioNTech (Germany) | Nucleic acid-based | Phase 3 | Combination mRNA SARS-CoV-2 (COVID-19) and influenza vaccine containing mRNA strains encoding the wild-type spike protein of SARS-CoV-2 and the spike protein of the Omicron BA.4/BA.5 subvariants as well as mRNA strands encoding the hemagglutinin of four different influenza strains Goal Akingbola 2025 (PMID: 40413212), Anderer 2024 (PMID: 39269723), NCT06178991 (P3), NCT06683352 (P1/2), NCT05596734 (P1/2), Press Release 11-4-2024, Press Release 8-16-2024, Press Release 5-6-2024, Press Release 3-20-2024, Press Release 10-26-2023, Press Release 12-9-2022, Press Release 11-3-2022, Developer Website: Pfizer, Developer Website: BioNTech
|
mRNA-1010 |
Moderna (US) | Nucleic acid-based | Phase 3 | Modified mRNA-based lipid nanoparticle vaccine candidate mRNA-1010 (in phase 3), a quadrivalent formulation with HA antigens from four seasonal influenza strains (A/H1N1, A/H3N2, and B/Yamagata- and B/Victoria-lineages) Goal Kandinov 2025 (PMID: 40174609), Soens 2025 (PMID: 39919447), Ananworanich 2025 (PMID: 38934845), Matz 2024 (PMID: 39416092), Lee 2023 (PMID: 37336877), Bahl 2022 , Dolgin 2021 (PMID: 34635829), Feldman 2019 (PMID: 31079849), Bahl 2017 (PMID: 28457665), Liang 2017 (PMID: 28958578), Lindgren 2017 (PMID: 29181005), NCT06602024 (P3), NCT05827978 (P3), NCT05566639 / EudraCT 2022-001638-12 (P3), NCT05415462 (P3), NCT05606965 (P2), NCT05868382 (P2), NCT04956575 (P1/2), NCT05397223 (P1), NCT03076385 (P1), NCT03345043 (P1), Press Release 6-30-2025, Press Release 5-1-2025, Press Release 2-14-2025, Press Release 1-13-2025, Press release 8-1-2024, Press Release 5-2-2024, Press Release 3-27-2024, Press Release 1-8-2024, Press Release 9-13-2023, Press Release 8-3-2023, Press Release 5-4-2023, Press Release 4-11-2023, Press Release 2-16-2023, Press Release 9-8-2022, Press Release 6-7-2022, Press Release 3-24-2022, Press Release 12-10-2021, Press Release 7-7-2021, Moderna Presentation May 2025, Moderna Presentation Jan 2025, Moderna Presentation Sep 2024, Moderna Presentation Jan 2024, Moderna Presentation 2022, Developer website: Moderna, Patent: Influenza Vaccine, Patent: Broad Spectrum Influenza Virus Vaccine
|
mRNA Flu/COVID-19 combination vaccine |
GSK (UK), CureVac (Germany) | Nucleic acid-based | Phase 2 | Combination mRNA Flu/COVID-19 vaccine with flu portion targeting multiple strains of the flu virus and the COVID-19 part focusing on the spike protein of the SARS-CoV-2 virus Goal |
mRNA-1020 and mRNA-1030 |
Moderna (US) | Nucleic acid-based | Phase 2 | Modified mRNA lipid nanoparticles mRNA-1020 and mRNA-1030 which incorporate HA and NA antigens to target more conserved regions of the virus Goal Bahl 2022 , Dolgin 2021 (PMID: 34635829), Feldman 2019 (PMID: 31079849), Bahl 2017 (PMID: 28457665), Liang 2017 (PMID: 28958578), Lindgren 2017 (PMID: 29181005), NCT05333289 (P1/2), Developer website, Press Release 9-13-2023, Press Release 4-11-2023, Press Release 2-16-2023, Press Release 4-11-2022, Press Release 3-24-2022, Press Release 12-10-2021, Moderna Presentation Jan 2025, Patent: Broad Spectrum Influenza Virus Vaccine
|
RIV3 + NVXC19 Combination Vaccine |
Sanofi (France) | Influenza virus-based | Phase 2 | Recombinant influenza vaccine RIV3 (FLUBLOK) combined with NVXC19 (Novavax COVID-19 vaccine) to prevent Influenza subtype A, influenza subtype B and coronavirus (SARS CoV-2) infection in individuals 50 years of age or older. Goal |
MVA-NP+M1 (VTP-100) |
Barinthus Biotherapeutics (UK) | Virus-vectored | Phase 2 | Modified vaccinia Ankara (MVA)–vectored construct expressing nucleoprotein (NP) and M1 protein (MVA-NP+M1); targets T cell responses to the nucleoprotein and matrix 1 core proteins of the influenza virus; co-administered with licensed quadrivalent inactivated influenza virus vaccine. Goal Evans 2024 (PMID: 38729196), Evans 2022 (PMID: 35305317), Valkenburg 2022 (PMID: 35305315), Butler 2021 (PMID: 34451976), Puksuriwong 2020 (PMID: 31740938), Swayze 2019 (PMID: 32089822), Folegatti 2019 (PMID: 30909516), Mullin 2016 (PMID: 26902548), Antrobus 2014 (PMID: 23831594), Mullarkey 2013 (PMID: 23589155), Powell 2013 (PMID: 23658773), Lillie 2012 (PMID: 22441650), Antrobus 2012 (PMID: 23118984), Berthoud 2011 (PMID: 21148512), Press Release 1-31-2020, Press Release 11-25-2019, NCT03883113 (P2), NCT03880474 (P2b- Terminated), NCT03300362 (P2b- Terminated), NCT00993083 (P2a), NCT03277456 (P1), NCT02014168 (P1- Terminated), NCT01465035 (P1), NCT00942071 (P1), Developer website: formerly known as Vaccitech
|
mRNA-1011 and mRNA-1012 |
Moderna (US) | Nucleic acid-based | Phase 2 | Modified mRNA lipid nanoparticles mRNA-1011/1012 which are seasonal penta-/hexa-valent vaccine candidates that includes more HA antigens (e.g. H3, H1) to expand strain matching Goal Isakova-Sivak 2025 (PMID: 39245056), Hsu 2024 (PMID: 39245055), Bahl 2022, Feldman 2019 (PMID: 31079849), Bahl 2017 (PMID: 28457665), Liang 2017 (PMID: 28958578), Lindgren 2017 (PMID: 29181005), Press Release 9-13-2023, Press Release 4-11-2023, Press Release 2-16-2023 , Press Release 3-24-2022, Press Release 12-10-2021 , Moderna Presentation Jan 2025, NCT05827068 (P1/2), Developer Website, Patent: Broad Spectrum Influenza Virus Vaccine
|
TIV-HD + NVXC19 Combination vaccine |
Sanofi (France) | Influenza virus-based | Phase 2 | Influenza protein-based trivalent vaccine TIV-HD (FLUZONE High-Dose) combined with adjuvanted recombinant NVXC19 (Novavax COVID-19 vaccine) to prevent Influenza subtype A, influenza subtype B and coronavirus (SARS CoV-2) infections in individuals 50 years of age or older. Goal |
M2SR |
CIVICs, NIAID (US), FluGen (US) | Influenza virus-based | Phase 2 | Novel single-replication (SR) platform for influenza A or B virus based on an otherwise wild-type influenza virus that does not express the M2 ion channel protein (M2-deficient); administered intranasally; aimed at eliciting cross-reactive antibodies against conserved HA stem and systemic and mucosal immune responses that block virus replication in the lung and provide cross-lineage protection against influenza virus. Quad M2SR, a quadrivalent form of this vaccine candidate, is currently in preclinical development.
Goal Hatta 2024 (PMID: 39591131), Hill-Batorski 2024 (PMID: 39012796), Sambhara 2024 (PMID: 39004095), Eiden 2024 (PMID: 39004096), Hill-Batorski 2023 (PMID: 37112710), Eiden 2023 (PMID: 36350017), Sarwar 2022 (PMID: 36560540), Eiden 2022 (PMID: 34323977), Eiden 2021, Moser 2019 (PMID: 31280945), Hatta 2018 (PMID: 30007825), Hatta 2017 (PMID: 28668565), Sarawar 2016 (PMID: 27595896), Hatta 2011 (PMID: 21272601), Watanabe 2009 (PMID: 19321619), News story 8-15-2024, Press Release 7-12-2024, News story 10-3-2022, Press release 11-9-2022, Press release 9-7-2022, Press Release 8-1-2022, Press Release 7-27-2022, Press release 6-22-2022, Press release 8-2-2021, Press Release 7-1-2021, Press release 5-25-2021, Press Release 8-28-2019, EudraCT 2017-004971-30 (P2a), NCT04960397 (P1b- Terminated), NCT05163847 (P1b), NCT04785794 (P1b), NCT03553940 (P1), NCT03999554 (P1), NCT02822105 (P1), Developer website
|
VXA-A1.1 oral tablet |
Vaxart (US) | Virus-vectored | Phase 2 | Replication-defective adenovirus type-5 vectored construct that expresses HA; includes a novel toll-like receptor 3 (TLR3 ligand) agonist as an adjuvant; administered orally in tablets designed to release the virus in the ileum, with the potential to stimulate cellular and mucosal immunity and serum antibody. Goal Braun 2023 (PMID: 37562075), Flitter 2022 (PMID: 35455342), McIlwain 2021 (PMID: 34784508), Rudenko 2020 (PMID: 31978351), Liebowitz 2020 (PMID: 31978354), Kolhatkar 2018 (PMCID: PMC6253129), Scallan 2016 (PMID: 27071663), Kim 2016 (PMID: 27881837), Liebowitz 2015 (PMID: 26333337), Peters 2013 (PMID: 23357198), NCT02918006 (P2), NCT03121339 (P1), NCT01688297 (P1), NCT01335347 (P1), Vaxart Investor Presentation Mar 2025, Vaxart Investor Presentation Oct 2024, Vaxart Investor Presentation Nov 2023, Press Release 1-22-2020, Press Release 7-9-2019, Developer website
|
OVX836 |
Osivax (France) | Non-VLP nanoparticles | Phase 2 | Self-assembling nanoparticle with multiple copies of full-length NP antigens; aimed at stimulating antibodies, cytotoxic T cells, and T helper cells. Goal Groth 2025, Jacobs 2024, Isakova-Sivak 2023 (PMID: 37517421), Leroux-Roels 2023 (PMID: 37517422), Withanage 2022 (PMID: 34653245), Leroux-Roels 2022 (PMID: 35464450), Del Campo 2021 (PMID: 34177921), Horizon 2020, Del Campo 2019 (PMID: 30701093), NCT06582277 (P2a), NCT05569239 (P2b), NCT05734040 (P2a), NCT05284799 (P2a), NCT05060887 / EudraCT 2021-002535-39 (P2a), NCT04192500 (P2a), NCT05184387 (Observational), NCT03594890 (P1), Press Release 6-5-2025, Press release 3-4-2025, Press Release 11-14-2024, Press Release 9-10-2024, Press Release 3-26-2024, Press Release 12-5-2023, Press Release 7-28-2023, Press Release 6-15-2023, Press Release 3-28-2023, Press Release 12-21-2022, Press Release 9-1-2022, Press Release 6-23-2022, Press Release 5-25-2022, Press Release 5-17-2022, Press Release 4-21-2022, Press release 12-2-2021, Press release 9-10-2020, Press release 7-8-2020, Press release 4-9-2020, Press Release 1-21-2020, Press release 12-5-2019, Development update 12-5-2019, Developer website, European Commission Funding
|
Chimeric HA constructs |
CIVICs, NIAID (US), Icahn School of Medicine at Mount Sinai (US) | Influenza virus-based | Phase 2 | Sequential combinations of different platforms, including LAIVs and inactivated split vaccines, with adjuvants, or of chimeric (cHA) or mosaic (mHA) constructs (cHA-LAIV-LAIV and cHA-LAIV-IIV, M2e), consisting of “exotic” HA head domains (from avian influenza viruses) and a conserved stalk domain; sequential administration with cHAs with different head domains and the same stalk domain; aimed at focusing humoral immunity on the highly conserved HA stalk domain. (Formerly: cHA-based LAIV combinations) Goal Puente-Massaguer 2025 (PMID: 40513214), Guthmiller 2025 (PMID: 40132593), Nguyen 2025 (PMID: 39937865), Dong and Wang 2024 (PMID: 38788629), Bliss 2024 (PMID: 38805853), Edgar 2023 (PMID: 37871218), Puente-Massaguer 2023 (PMID: 37703367), Puente-Massaguer 2023 (PMID: 37342504), Dhakal 2022 (PMID: 33293159), Meade 2022 (PMID: 36533948), Aydillo 2022 (PMID: 36496417), Zhu 2022 (PMID: 35594401), Isakova-Sivak 2022 (PMID: 35461523), Folschweiller 2022 (PMID: 35461522), Guthmiller 2021, Nachbagauer 2021 (PMID: 33288923), Liu 2021 (PMID: 33440898), Bernstein 2020 (PMID: 31630990), Destexhe 2020 (PMID: 32119974), Broecker 2019 (PMID: 31341648), Sun 2019 (PMID: 31540436), Krammer 2019 (PMID: 30715353), Nachbagauer 2019 (PMID: 31839997), Liu 2019 (PMID: 31105689), Choi 2019 (PMID: 31032479), Sunwoo 2018 (PMID: 30223475), Nachbagauer 2018 (PMID: 30044403), Nachbagauer 2017 (PMID: 29263881), Nachbagauer 2016 (PMID: 26719251), EudraCT: 2017-001584-20 (P1/2), NCT03275389 (P1), NCT03300050 (P1), NCT02415842 (Observational), Press Release 6-30-2022, Press Release 7-16-2020, Press Release 12-7-2020, Press Release 5-1-2019, News Story 12-7-2020, NIH Funding, Patent: Immunogenic Compositions Containing Inactivated Influenza A Virus And CpG Oligonucleotide Adjuvant And Uses Thereof
|
mRNA constructs |
Sanofi (France) | Nucleic acid-based | Phase 2 | Monovalent, quadrivalent and hexavalent mRNA vaccine constructs; differing in the LNP containing the mRNA Formerly: mRNA NA Goal Chivukula 2021 (PMID: 34916519), Dolgin 2021 (PMID: 34635829), NCT06744205 (P1/2), NCT06361875 (P1/2), NCT05650554 (P1/2), NCT05624606 (P1/2), NCT05553301 (P1/2), NCT05829356 (P1), NCT05426174 (P1), NCT06118151 (P1), Sanofi Investor Presentation, Press Release 6-22-2021, Patent: Multivalent influenza vaccines, Patent: Lipid nanoparticles for delivering mRNA vaccines, Patent: Multivalent Influenza mRNA Vaccines, Developer website: Sanofi
|
FP-01.1 |
Immune Targeting Systems (now Altimmune) (US) | Recombinant proteins | Phase 2 | Novel construct consisting of 6 synthetic peptides linked to an inert fluorocarbon chain, encapsulating multiple conserved epitopes (NP, M, and PB1/PB2); aimed at generating T cell responses to divergent influenza strains. Goal |
saRNA |
Pfizer (US) | Nucleic acid-based | Phase 2 | Self-amplifying ribonucleic acid (saRNA) vaccine delivered intramuscularly Goal |
deltaFLU |
Vivaldi Biosciences (US) | Influenza virus-based | Phase 2 | Self-adjuvanted, nonstructural protein 1 (NS1)-deficient, replication-deficient LAIV; administered as a nasal spray; aimed at stimulating interferon, mucosal cross-neutralizing IgA antibodies, systemic cytotoxic T-cell response (Th1) and B-cell response with cross-neutralizing antibodies and memory T-cell response.
Goal Cnossen 2025, Nicolodi 2019 (PMID: 31155415), Morokutti 2014 (PMID: 24560674), Mossler 2013 (PMID: 24183981), Krenn 2011 (PMID: 21490925), Wacheck 2010 (PMID: 20039806), NCT01369862 (P1/2), NCT01078701 (P2a), NCT03745274 (P1), NCT00724997 (P1), Press Release 4-17-2025, Press Release 12-18-2023, Press Release 6-5-2023, Press Release 3-29-2023, Press Release 11-29-2021, Press Release 11-23-2020, Press Release 6-19-2019, Press Release 4-4-2018, Press Release 2-12-2018, Developer website, NIH Funding
|
Multivalent Modified mRNA |
GSK (UK), CureVac (Germany) | Nucleic acid-based | Phase 2 | An mRNA-based modified, multivalent construct including the 4 WHO recommended influenza strain antigens. Goal Lutz 2017 (PMID: 29263884), Kallen 2013 (PMID: 23921513), Petsch 2012 (PMID: 23159882), NCT06431607 (P2a), NCT05823974 (P1/2), NCT05252338 (P1), Press Release 6-12-2025, Press Release 11-12-2024, Press Release 9-12-2024, News story 9-12-2024, Press Release 7-3-2024, Press Release 4-4-2024, Press Release 11-1-2023, Press Release 9-12-2023, Press Release 5-8-2023, Press Release 4-25-2023, Press Release 1-30-2023, Press Release 2-10-2022, GSK presentation 2024, GSK Presentation 2023, Patent: Influenza mRNA Vaccines, Developer website: GSK, Developer website: CureVac
|
NasoVAX |
Altimmune (US) | Virus-vectored | Phase 2 | Replication-deficient adenovirus serotype 5 construct designed to express influenza HA (H1) in nasal epithelial cells; administered as a nasal spray. Goal |
FLU-v |
ConserV Bioscience (UK), Imutex (UK) | Recombinant proteins | Phase 2 | Peptide-based construct derived from conserved regions of internal proteins (M1, IAV-NP, IBV-NP, and M2) aiming to provide a broadly protective immune response against influenza A and B through viral clearance by cytotoxic T cell responses. Goal Oftung 2022 (PMID: 36146606), Pleguezuelos 2020 (PMID: 32150750), Pleguezuelos 2020 (PMID: 32194999), Abbasi 2020 (PMID: 32286631), Van Doorn 2017 (PMID: 28376743), Pleguezuelos 2015 (PMID: 26084515), Pleguezuelos 2015 (PMID: 25994549), Pleguezuelos 2012 (PMID: 22575166), Stoloff 2007 (PMID: 17668898), Press release 3-16-2020, Press release 1-11-19, NCT02962908 / EudraCT 2015-001932-38 (P2b), NCT03180801 / EudraCT 2016-002134-74 (P2b), NCT01226758 (P1b), NCT01181336 (P1b), Developer Website: ConserV Bioscience, Developer website: Imutex, NIH Funding
|
G1 mHA |
Janssen Vaccines and Prevention, J&J (Netherlands) | Recombinant proteins | Phase 2 | Group 1 HA stem-based antigen, based on an approach that removes the immunodominant HA head region while stabilizing the structure of the stem region; aimed at inducing broadly neutralizing antibodies. (Formerly: Mini-HA) Goal |
FluMos self-assembling nanoparticle |
NIAID (US) | Non-VLP nanoparticles | Phase 1 | Uses computationally designed nanoparticle immunogens that controllably display diverse HA trimers in an ordered array on self-assembling protein nanoparticles; aimed at eliciting both HAI activity and protective stem-directed neutralizing antibodies against heterosubtypic influenza viruses. FluMos-v2 is a mosaic hexavalent influenza nanoparticle vaccine composed of full-length HA trimers of 4 influenza A strains (H1: A/Idaho/07/2018; H2: A/Singapore/1/1957; H3: A/Perth/1008/2019; H3: A/Darwin/106/2020) and two influenza B lineages (B/Victoria: B/Colorado/06/2017; B/Yamagata: B/Phuket/3073/2013). FluMos-v1 is a mosaic array of heterotypic influenza HA antigens (from H1, H3, HBV, and HBY) displayed on a single nanoparticle. Both candidates are aimed at eliciting broadly neutralizing antibodies by enhancing immune responses to conserved epitopes present in the HAs of all influenza strains contained in the nanoparticle. (Formerly: FluMos-v1) Goal Yang 2024 (PMID: 38402303), Alabanza 2023 (PMID: 37451877), Yang 2023 (PMID: 36906406), Shajahan 2023 (PMID: 36723411), Boyoglu-Barnum 2021 (PMID: 33762730), Kanekiyo 2019 (PMID: 30742080), Krammer 2019 comment (PMID: 30742079), Georgiev 2018 (PMID: 29451984), Kanekiyo 2013 (PMID: 23698367), NCT06863142 (P1), NCT05968989 (P1), NCT04896086 (P1), News Story 9-27-2023, Press Release 9-15-2023, Press Release 6-1-2021, Press Release 5-6-2021, NIH Funding, NIH Funding, Developer Website: NIAID
|
Ad4-H5-VTN |
NIAID (US) | Virus-vectored | Phase 1 | Replication-competent adenovirus type 4 encoding influenza virus H5 HA (Ad4-H5-Vtn) administered as an oral capsule or via tonsillar swab or nasal spray, as a potential platform for inducing durable and systemic mucosal immunity against influenza glycoproteins. Goal |
Stabilized headless HA stem nanoparticles |
NIAID (US) | Non-VLP nanoparticles | Phase 1 | A self-assembling ferritin nanoparticle (H1ssF) containing HA stem epitopes, aimed at eliciting HA stem-specific antibody responses against heterologous influenza strains. Goal Crofts 2025 (PMID: 40263387), Ataca 2025 (PMID: 39580804), Sangesland 2025, van Diemen 2025 (PMID: 39947075), Mantus 2025 (PMID: 39742506), Casazza 2024 (PMID: 39289377), Andrews 2023 (PMID: 37075126), Widge 2023 (PMID: 37075129), Moin 2022 (PMID: 36356572), Darricarrère 2021 (PMID: 33658355), Corbett 2019 (PMID: 30808695), Yassine 2015 (PMID: 26301691), Press Release 4-20-2023, Press Release 3-3-2021, NIH Press Release 2019, NCT04579250 (P1), NCT03814720 (P1), NIH Funding, Developer website: NIAID
|
sa-mRNA (SQ012) |
CSL Seqirus (Australia) | Nucleic acid-based | Phase 1 | Self-amplifying mRNA influenza vaccine candidate developed to co-express HA and NA Formerly: sa-mRNA bicistronic vaccine Goal |
Micro-consensus DNA vaccine |
Wistar Institute (US), Inovio Pharmaceuticals (US) | Nucleic acid-based | Phase 1 | Synthetic microconsensus DNA platform based on 4 plasmid-encoding microconsensus H1 and H3 HA antigens, each containing a limited consensus sequence based on analysis of a subset of primary sequences of H1 and H3 HA antigens; aimed at inducing protective levels of HAI titers to diverse isolates of H1N1 and H3N2 influenza; delivered by intradermal/intramuscular electroporation (EP); aimed at eliciting antibody and T-cell responses. Goal Xu 2020 (PMID: 32328416), Yan 2018 (PMID: 29100705), Elliott 2018 (PMID: 30062926), Yan 2014 (PMID: 24631084), Kichaev 2013 (PMID: 23954979), NCT01587131 (P1), NCT01405885 (P1), NCT01403155 (P1), NCT01184976 (P1), NCT01142362 (P1), Developer website: Wistar Institute, Developer website: Inovio Pharmaceuticals
|
CodaVax |
Codagenix (US) | Influenza virus-based | Phase 1 | LAIV generated through synthetic attenuated virus-engineering (SAVE); uses an algorithm to “de-optimize” the influenza HA and NA gene segments for reduced translation in human cells, resulting in virus attenuation while preserving the immunogenicity of wild-type virus; aimed at stimulating an immune response against influenza viruses from multiple seasons and multiple decades (e.g. influenza viruses from 1970s and 1930s). Goal Stauft 2019 (PMID: 31609986), Broadbent 2016 (PMID: 26655630), Yang 2013 (PMID: 23690603), Mueller 2010 (PMID: 20543832), NCT05223179 (P1), NCT04146623 / ACTRN12618002041235 (P1), NCT03926416 (P1), Press Release 6-14-2022, Patent: Parenterally Administrable Influenza Vaccine and Uses Thereof, Developer website
|
fH1/DSP-0546LP |
Sumitomo Pharma (Japan), National Institutes of Biomedical Innovation, Health and Nutrition (Japan) | Recombinant proteins | Phase 1 | Post-fusion HA antigens adjuvanted with a newly developed liposomal SA-2 containing a synthetic toll-like receptor (TLR) 7 agonist (DSP-0546) compound. Goal |
EBS-UFV-001 (UFluA) |
Emergent BioSolutions (US) | Non-VLP nanoparticles | Phase 1 | Nanoparticle based vaccine that self-assembles during production and that displays a cross-reactive HA antigen for influenza virus A groups 1 and 2. The self-assembling HA stabilized stem nanoparticle technology was developed by and licensed from NIAID. UFluA is comprised of DP-UFluA (1:1 A1-ssnp and A2-ssnp antigens) and contains aluminum hydroxide and CpG adjuvants. Goal |
H1ssF_3928 mRNA-LNP |
CIVICs, NIAID (US) | Nucleic acid-based | Phase 1 | mRNA expressing influenza H1 stabilized stem (H1ss) covalently fused to H. pylori ferritin (F) Goal |
M2e VLP |
Russian Academy of Sciences (Russia), VA Pharma (Russia) | Virus-like particles (VLP) | Phase 1 | Recombinant VLPs displaying multiple copies of M2e aimed at inducing M2e-antibody responses. (Formerly: HBc-4M2eh (Uniflu)) Goal |
mRNA-1230 |
Moderna (US) | Nucleic acid-based | Phase 1 | Multi-component mRNA SARS-CoV-2 (COVID-19), influenza and respiratory syncytial virus (RSV) vaccine administered intramuscularly. Goal |
sa-RNA (ARCT-2138) |
Arcturus Therapeutics (US), CSL Seqirus (Australia) | Nucleic acid-based | Phase 1 | Self-amplifying RNA seasonal influenza vaccine (ARCT-2138) administered intramuscularly Goal |
BPL-1357 |
NIAID (US) | Influenza virus-based | Phase 1 | BPL-1357 contains 4 whole inactivated avian influenza virus strains: H7N3, H5N1, H3N8, and H1N9; administered either intranasally or intramuscularly; intended to induce mucosal immunity similar to the immune response following influenza infection including cellular and B cell responses. Goal Tudor Giurgea 2025, Bannerjee 2025, Larkin 2022 (PMID: 35943485), Park 2022, Park 2021, NCT05027932 (P1), Press Release 5-1-2025, Press release 8-19-2022, Press release 7-13-2022, Press release 6-28-2022, News Story 5-9-2025, News Story 5-5-2025, News Story 5-3-2025, News story 5-1-2025, Patent: Broadly Protective Inactivated Influenza Virus Vaccine, Developer website: NIAID
|
ChAdOx1 NP+M1 and MVA NP+M1 in heterologous prime-boost regimens |
Jenner Institute, University of Oxford (UK) | Virus-vectored | Phase 1 | Two-dose heterologous viral vectored constructs: modified vaccinia virus Ankara (MVA) and the chimpanzee adenovirus ChAdOx2 expressing conserved influenza virus antigens, nucleoprotein (NP) and matrix protein-1 (M1); aimed at stimulating T-cell responses to influenza virus. Goal |
HA2 HA-ferritin nanoparticle |
NIAID (US) | Non-VLP nanoparticles | Phase 1 | The HA2 HA-ferritin nanoparticle (HA-F A/Sing) vaccine displays 8 HA trimers from A/Singapore/1/57 (H2N2) influenza, designed to induce induce cross-reactive polyclonal antibodies to conserved epitopes in the receptor-binding site, medial junction, and central stem of HA. Goal Spangler 2025 (PMID: 40023164), Yang 2024 (PMID: 38717904), Yang 2023 (PMID: 37781590), Nelson 2022 (PMID: 36289232), Houser 2022 (PMID: 35115706), Andrews 2022 (PMID: 35115707), Kelly 2020 (PMID: 32434990), Darricarrère 2018 (PMID: 30185594), NCT03186781 (P1), Press Release 5-11-2022, Developer website: NIAID
|
H1 HA mRNA-LNP |
CIVICs, NIAID (US) | Nucleic acid-based | Phase 1 | An mRNA encoding the full-length HA of influenza A/California/07/2009 (H1N1). Goal |
